A company trying to bring a new weight loss device to the U.S. said it completed enrollment in its multi-center U.S. pivotal trial in just 62 days. The website the company set up to recruit participants attracted 24,000 inquiries from patients wanting to enroll in the SMART trial. The FDA granted Obalon Therapeutics (Carlsbad, California) an investigational device exemption to run the trial at 15 U.S. sites only four months ago.
Read More
